CRBU
Price
$0.47
Change
-$0.00 (-0.00%)
Updated
Oct 14, 11:06 AM (EDT)
Capitalization
131.87M
27 days until earnings call
Intraday BUY SELL Signals
EDIT
Price
$2.32
Change
-$0.12 (-4.92%)
Updated
Oct 14, 12:30 PM (EDT)
Capitalization
385.49M
26 days until earnings call
Intraday BUY SELL Signals
Interact to see
Advertisement

CRBU vs EDIT

CRBU vs EDIT Comparison Chart in %
loading
loading
View a ticker or compare two or three
VS
CRBU vs. EDIT commentary
Oct 14, 2026

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is CRBU is a Hold and EDIT is a Hold.

Interact to see
Advertisement
SUMMARIES
A.I.Advisor
a Summary for CRBU with price predictions
Oct 13, 2026

Momentum Indicator for CRBU turns negative, indicating new downward trend

CRBU saw its Momentum Indicator move below the 0 level on October 01, 2026. This is an indication that the stock could be shifting in to a new downward move. Traders may want to consider selling the stock or exploring put options. Tickeron's A.I.dvisor looked at 88 similar instances where the indicator turned negative. In 81 of the 88 cases, the stock moved further down in the following days. The odds of a decline are at 90%.

Price Prediction Chart

Technical Analysis (Indicators)

Bearish Trend Analysis

The Moving Average Convergence Divergence Histogram (MACD) for CRBU turned negative on October 06, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 42 similar instances when the indicator turned negative. In 40 of the 42 cases the stock turned lower in the days that followed. This puts the odds of success at 90%.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where CRBU declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 88%.

The Aroon Indicator for CRBU entered a downward trend on October 13, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.

Bullish Trend Analysis

The RSI Indicator shows that the ticker has stayed in the oversold zone for 6 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an Uptrend is expected.

Following a +3.25% 3-day Advance, the price is estimated to grow further. Considering data from situations where CRBU advanced for three days, in 204 of 256 cases, the price rose further within the following month. The odds of a continued upward trend are 80%.

CRBU may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.

Fundamental Analysis (Ratings)

The Tickeron Valuation Rating of 19 (best 1 - 100 worst) indicates that the company is slightly undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (1.344) is normal, around the industry mean (26.782). P/E Ratio (0.000) is within average values for comparable stocks, (43.395). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (0.000) among similar stocks. P/S Ratio (11.641) is also within normal values, averaging (437.542).

The Tickeron Price Growth Rating for this company is 97 (best 1 - 100 worst), indicating slightly worse than average price growth. CRBU’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron SMR rating for this company is 98 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron PE Growth Rating for this company is 100 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. CRBU’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.

A.I.Advisor
a Summary for EDIT with price predictions
Oct 13, 2026

Momentum Indicator for EDIT turns negative, indicating new downward trend

EDIT saw its Momentum Indicator move below the 0 level on October 13, 2026. This is an indication that the stock could be shifting in to a new downward move. Traders may want to consider selling the stock or exploring put options. Tickeron's A.I.dvisor looked at 86 similar instances where the indicator turned negative. In 80 of the 86 cases, the stock moved further down in the following days. The odds of a decline are at 90%.

Price Prediction Chart

Technical Analysis (Indicators)

Bearish Trend Analysis

The Stochastic Oscillator may be shifting from an upward trend to a downward trend. In 42 of 48 cases where EDIT's Stochastic Oscillator exited the overbought zone, the price fell further within the following month. The odds of a continued downward trend are 88%.

EDIT moved below its 50-day moving average on October 12, 2026 date and that indicates a change from an upward trend to a downward trend.

The 10-day moving average for EDIT crossed bearishly below the 50-day moving average on September 11, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In 13 of 15 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are 87%.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where EDIT declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 90%.

The Aroon Indicator for EDIT entered a downward trend on October 07, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.

Bullish Trend Analysis

The Moving Average Convergence Divergence (MACD) for EDIT just turned positive on October 05, 2026. Looking at past instances where EDIT's MACD turned positive, the stock continued to rise in 37 of 49 cases over the following month. The odds of a continued upward trend are 76%.

Following a +5.46% 3-day Advance, the price is estimated to grow further. Considering data from situations where EDIT advanced for three days, in 180 of 225 cases, the price rose further within the following month. The odds of a continued upward trend are 80%.

EDIT may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.

Fundamental Analysis (Ratings)

The Tickeron Valuation Rating of 35 (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (3.662) is normal, around the industry mean (26.782). P/E Ratio (0.000) is within average values for comparable stocks, (43.395). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (0.000) among similar stocks. P/S Ratio (5.855) is also within normal values, averaging (437.542).

The Tickeron Price Growth Rating for this company is 61 (best 1 - 100 worst), indicating steady price growth. EDIT’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron SMR rating for this company is 99 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron PE Growth Rating for this company is 100 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. EDIT’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.

FUNDAMENTALS RATINGS
EDIT: Fundamental Ratings
EDIT
OUTLOOK RATING
1..100
14
VALUATION
overvalued / fair valued / undervalued
1..100
35
Fair valued
PROFIT vs RISK RATING
1..100
100
SMR RATING
1..100
99
PRICE GROWTH RATING
1..100
61
P/E GROWTH RATING
1..100
100
SEASONALITY SCORE
1..100
50

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

TECHNICAL ANALYSIS
Technical Analysis
CRBUEDIT
RSI
ODDS (%)
Bullish Trend 1 day ago
77%
N/A
Stochastic
ODDS (%)
N/A
Bearish Trend 1 day ago
88%
Momentum
ODDS (%)
Bearish Trend 1 day ago
90%
Bearish Trend 1 day ago
90%
MACD
ODDS (%)
Bearish Trend 1 day ago
90%
Bullish Trend 1 day ago
76%
TrendWeek
ODDS (%)
Bearish Trend 1 day ago
89%
Bearish Trend 1 day ago
90%
TrendMonth
ODDS (%)
Bearish Trend 1 day ago
90%
Bearish Trend 1 day ago
89%
Advances
ODDS (%)
Bullish Trend 15 days ago
80%
Bullish Trend 6 days ago
80%
Declines
ODDS (%)
Bearish Trend 6 days ago
88%
Bearish Trend 1 day ago
90%
BollingerBands
ODDS (%)
Bullish Trend 1 day ago
74%
Bullish Trend 1 day ago
83%
Aroon
ODDS (%)
Bearish Trend 1 day ago
90%
Bearish Trend 1 day ago
90%
COMPARISON
Comparison
Oct 14, 2026
Stock price -- (CRBU: $0.47 vs. EDIT: $2.44)
Brand notoriety: CRBU and EDIT are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: CRBU: 156% vs. EDIT: 81%
Market capitalization -- CRBU: $131.87M vs. EDIT: $385.49M
CRBU [@Biotechnology] is valued at $131.87M. EDIT’s [@Biotechnology] market capitalization is $385.49M. The market cap for tickers in the [@Biotechnology] industry ranges from $58 to $133.74B. The average market capitalization across the [@Biotechnology] industry is $2.21B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is overvalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

CRBU’s FA Score shows that 1 FA rating(s) are green while EDIT’s FA Score has 0 green FA rating(s).

  • CRBU’s FA Score: 1 green, 4 red.
  • EDIT’s FA Score: 0 green, 5 red.
According to our system of comparison, EDIT is a better buy in the long-term than CRBU.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

CRBU’s TA Score shows that 3 TA indicator(s) are bullish while EDIT’s TA Score has 3 bullish TA indicator(s).

  • CRBU’s TA Score: 3 bullish, 4 bearish.
  • EDIT’s TA Score: 3 bullish, 6 bearish.
According to our system of comparison, CRBU is a better buy in the short-term than EDIT.

Price Growth

CRBU (@Biotechnology) experienced а -58.59% price change this week, while EDIT (@Biotechnology) price change was -10.44% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was -7.22%. For the same industry, the average monthly price growth was -17.98%, and the average quarterly price growth was -18.86%.

Reported Earning Dates

CRBU is expected to report earnings on Nov 10, 2026.

EDIT is expected to report earnings on Nov 09, 2026.

Industries' Descriptions

@Biotechnology (-7.22% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

View a ticker or compare two or three
CRBU
Daily Signal:
Gain/Loss:
EDIT
Daily Signal:
Gain/Loss:
Interact to see
Advertisement
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
ETFs / NAMEPrice $Chg $Chg %
DUBS43.710.03
+0.07%
Aptus Large Cap Enhanced Yield ETF (DUBS)
CBXA23.97N/A
N/A
Calamos Bitcoin 90 Series Structured Alt Protection ETF - April
XBAP43.20N/A
N/A
Innovator U.S. Equity Accelerated 9 Buffer ETF - April (XBAP)
AZTD30.95-0.13
-0.43%
Aztlan Global Stock Selection DM SMID ETF (AZTD)
EVT27.89-0.19
-0.68%
Eaton Vance Tax-Advantaged Dividend Income Fund

CRBU and

Correlation & Price change

A.I.dvisor indicates that over the last year, CRBU has been loosely correlated with AXON. These tickers have moved in lockstep 50% of the time. This A.I.-generated data suggests there is some statistical probability that if CRBU jumps, then AXON could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To CRBU
1D Price
Change %
CRBU100%
-5.41%
AXON - CRBU
50%
Loosely correlated
-0.26%
CRSP - CRBU
46%
Loosely correlated
-2.81%
RXRX - CRBU
44%
Loosely correlated
-4.36%
EDIT - CRBU
44%
Loosely correlated
-11.09%
ABSI - CRBU
43%
Loosely correlated
-5.89%
More